News Oxurion Announces Key Amendments to Atlas and Kreos/Pontifax Agreements Enabling KALAHARI Trial to Progress to Topline Results in 2023 Continue Reading Previous Verona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPDNext Accenture Invests in Open Cosmos to Expand Access to Satellite Data Related Stories News UXLINK Year-End Review 2024: Celebrating a Year of Innovation, Growth, and Success News Atlas Lithium Accelerates Production Readiness with Key Executive Appointments News World’s first high-standard negative-pressure isolation ward built with MiC technology completes historical mission News Hola Prime Establishes Industry’s First Dedicated Risk Compliance Team News Boba Mint Provides Update on $1.5 Million Financing News Predictive AI Creating Trillions of Dollars of Economic Value: Jim Harris Leads Expert Panel at CES 2025 in Las Vegas
